Evidence map›Paper›PMID 42216435›Full record

ArticleAdvanced healthcare materials2026

Functional Blood-Brain Barrier Crossing by Biomimetic M13 Phage Vectors for Targeted Neuronal Delivery.

Silvia Vercellino, Lucia Pappagallo, Francesca De Chirico, Luca Boselli, Hazem Ahmed, Luca Spagnoletti, Giovanni Pittaluga, Paolo Emidio Costantini, Matteo Calvaresi, Pier Paolo Pompa and 3 more

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Silvia VercellinoCenter for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, Genova, Italy.
Lucia PappagalloCenter for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, Genova, Italy.ORCID https://orcid.org/0009-0005-3740-007X
Francesca De ChiricoFondazione Pisana per la Scienza ONLUS, San Giuliano Terme, Pisa, Italy.
Luca BoselliNanobiointeractions & Nanodiagnostics, Istituto Italiano di Tecnologia (IIT), Genova, Italy.ORCID https://orcid.org/0000-0002-2732-5484
Hazem AhmedCenter for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, Genova, Italy.ORCID https://orcid.org/0000-0003-0034-2978
Luca SpagnolettiCenter for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, Genova, Italy.
Giovanni PittalugaCenter for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, Genova, Italy.
Paolo Emidio CostantiniDipartimento di Farmacia e Biotecnologie, Alma Mater Studiorum - Università di Bologna, Bologna, Italy.ORCID https://orcid.org/0000-0003-1597-6404
Matteo CalvaresiIRCCS AOUBO Sant'Orsola - Laboratory of Preclinical and Translational Research in Oncology (PRO), Bologna, Italy.ORCID https://orcid.org/0000-0002-9583-2146
Pier Paolo PompaNanobiointeractions & Nanodiagnostics, Istituto Italiano di Tecnologia (IIT), Genova, Italy.ORCID https://orcid.org/0000-0001-7549-0612
Alberto DanielliDipartimento di Farmacia e Biotecnologie, Alma Mater Studiorum - Università di Bologna, Bologna, Italy.ORCID https://orcid.org/0000-0002-9414-9898
Fabio BenfenatiCenter for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, Genova, Italy.ORCID https://orcid.org/0000-0002-0653-8368
Valentina CastagnolaFondazione Pisana per la Scienza ONLUS, San Giuliano Terme, Pisa, Italy.ORCID https://orcid.org/0000-0002-8651-5958

Funding

ERA-NET Joint Programme for Neurodegenerative Diseases 2020 under the Neurophage 2022A5YWJJERA-NET Joint Programme for Neurodegenerative Diseases 2020 under the Neurophage ER-2020-23669249Fondazione AIRC per la ricerca sul cancro ETS ID22894Fondazione Pisana per la Scienza FPS grant Vassili Fotis in Neuroscience 2024HORIZON EUROPE Marie Sklodowska-Curie Actions 101108198Michael J. Fox Foundation for Parkinson's Research MJFF-021697Ministero dell'Università e della Ricerca 2020WMSNBLMinistero dell'Università e della Ricerca 2022A5YWJJ
6 · The paper itself

Abstract

The blood-brain barrier (BBB) is a highly selective gatekeeper. While providing essential protection against pathogens, BBB also poses a major challenge by restricting the delivery of systemically administered therapeutics. Consequently, there is a pressing need for innovative strategies that can efficiently and selectively target neuronal populations to treat diverse brain disorders. Nanomaterials enable transcellular transport across the endothelial layer; however, given the biomolecular corona paradigm, designing biomimetic hybrid nanoconstructs that preserve and leverage biological functionality within a complex physiological environment is more promising. Here, we investigated the potential of M13 bacteriophages as biocompatible and versatile nanovectors across the BBB. M13 phages exhibited: (i) a high cargo capacity within the main protein capsomer (here exploited for fluorescent labeling); (ii) offered genetic flexibility for ligand display; (iii) showed a natural propensity to efficiently cross the endothelial layer via specific intracellular pathways; (iv) maintained their structure and functionality intact. We also demonstrate that M13 phages engineered to target specific neuronal populations via single-domain antibody display retain their specificity after BBB translocation and in a protein- and cell-crowded environment. Overall, our results provide mechanistic insights emphasizing an unprecedented field of application for (engineered) M13 phages as biomimetic nanotools for targeting and delivery across the BBB.

Indexed as

Bacteriophage M13Biomimetic MaterialsBlood-Brain BarrierNeuronsAnimalsHumansblood‐brain barrierendothelial cellsM13 bacteriophageneuronal targeting

Identifiers

PMID42216435
PMCPMC13410473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.